Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday. The company’s shares closed

Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday. The company’s shares closed
Yesterday it was reported that a Director at Bio-Techne (TECH – Research Report), Robert Baumgartner, exercised options to sell 5,000
Yesterday it was reported that the CFO of Bio-Techne (TECH – Research Report), James Hippel, exercised options to sell 15,909
In a report released yesterday, Atlantic Equities from Atlantic Equities initiated coverage with a Buy rating on Bio-Techne (TECH –
Yesterday it was reported that the President-Protein Sciences of Bio-Techne (TECH – Research Report), David Eansor, exercised options to sell
Yesterday, the President-Protein Sciences of Bio-Techne (TECH – Research Report), David Eansor, sold shares of TECH for $275.6K. Following David
Yesterday it was reported that the CEO of Bio-Techne Corporation (TECH – Research Report), Charles Kummeth, exercised options to buy